According to Google’s Our Mobile Planet research, smartphone penetration increased 13% over last year, with 44% of the U.S. population now owning a smartphone and 66% of those accessing the Internet on a daily basis. That smartphone stat doesn’t put the U.S. in the top tier globally, though. Australia, the U.K., Sweden, Norway, Saudi Arabia, and the UAE all have smartphone uptake rates over 50%.
The recent flak service providers like Verizon and Sprint caught with capping dubiously titled "unlimited data" plans hasn’t seemed to slow consumers’ fervor for utilizing their smartphones to shop, with an overwhelming 96% claiming to have researched a product or service on their phone and 57% conducting general searches every day.
Among the other stats: 89% of smartphone users notice mobile ads and 66% visit a business online or in-store after a local search.
Marketers should keep in mind, however, that much like searching on a traditional computer, SEO still plays a crucial role, as 61% of smartphone users only look at the first page of results. That being said, fleeting attention spans can be channeled into successful campaigns by capitalizing on the fact that 86% of people use their smartphone while consuming other media: 52% watching TV, 51% listening to music on their smartphone, and 34% watching movies.
 |
| Tokyo Skytree Tower |
The 634-meter (2,080 feet) structure in eastern Tokyo sits in a retail complex housing more than 300 shops and restaurants, a planetarium and an aquarium. Developer Tobu Railway Co. (9001) expects the project to draw 32 million visitors in its first year, surpassing the numbers at Tokyo Disney Resort. Tobu, whose revenue has fallen for five years, will also get a 28.3 billion yen ($352 million) sales boost in the year ending March 31, according to Kazuhiko Hirata, a general manager for finance.
The 143 billion yen development, which took four years to build, follows last month’s opening of Tokyu Corp. (9005)’s 34-story entertainment complex in the Shibuya shopping district and East Japan Railway Co. (9020)’s ongoing 50 billion-yen renovation of Tokyo Station. The companies are taking advantage of land they own around stations to generate new income and lure more travelers as Japan’s shrinking birthrate threatens commuter traffic.
“People will use the Tobu line to go to Tokyo Skytree and they will shop in Tobu shops when they get there,” said Masayuki Kubota, who oversees the equivalent of $2 billion in assets in Tokyo at Daiwa SB Investments Ltd. “It’s a very good investment.” He doesn’t own Tobu shares, he said.
The development will boost Tobu’s operating profit by 3.2 billion yen in the year ending March 31, according to Hirata. The company will have as many as eight trains an hour running from the Asakusa terminus to the development’s closest station, which has been renamed Tokyo Skytree.
856 Million Passengers
Tobu, which operates routes to the north of the capital, carried 856 million passengers in the year ended March 31. The company is the third biggest by ticket sales among the 11 major train operators in Tokyo and surrounding cities, according to JR East. (9022) The region is home to 35 million people. By contrast, Amtrak carried 30 million passengers in the U.S. in the year ended September 2011.
Tobu, which also operates buses, hotels, shopping centers, department stores, golf courses and sports clubs, fell 2.3 percent to 387 yen in Tokyo trading yesterday. It’s jumped 24 percent in the past year, compared with an 11 percent decline for the benchmark Topix Index.
Earthquake-Resistant
The Skytree, opening about a year after a temblor and tsunami devastated parts of northern Japan, stands on three legs with a central column in the style of a pagoda to make it more earthquake-resistant. Its steel frame changes from a triangle at the base to a circle at the top, and its curves and arches reflect a traditional Samurai sword, according to Tobu’s website.
The tower, which cost 65 billion yen on its own, will have two observation decks, one at 350 meters and another at 450 meters. A trip to the lower deck will cost 2,000 yen. Visits up the tower are fully booked through July 11, said Kenji Aoyagi, a Tobu spokesman.
The tower surpassed the 600-meter Canton Tower in Guangzhou, China, as the world’s tallest, according to theCouncil on Tall Buildings and Urban Habitat. Dubai’s 828-meter Burj Khalifa is the tallest building, according to the council.
The new tower is also about double the height of Japan’s previous record-holder, the 333-meterTokyo Tower, which opened in 1958. Six TV stations, including state-owned NHK, will start using the Skytree instead of the older tower for transmissions next year.
Geishas, Temple
Skytree looms over Tokyo’s Asakusa district, previously one of the city’s main entertainment areas and still home to geishas and traditional Japanese restaurants. The area also houses Senso-ji temple, a popular tourist site, famed for Kaminarimon, Thunder Gate.
Property prices in Sumida City, which includes Asakusa and Skytree, are the third-lowest of Tokyo’s 23 wards, according to the Ministry of Land, Infrastructure, Transport and Tourism. Commercial land prices have fared better than other Tokyo wards this year, falling 1 percent, compared with an average 2.1 percent decline.
“As a local, I’m very happy,” said Naoyuki Sato, 56, who runs a restaurant near the tower and has lived in the area all his life. “It’ll be a new symbol for Japan. It’s a ray of hope after the earthquake.”
Shrinking Population
Japan’s population peaked at 127.1 million people in 2005 and has been shrinking since, according to figures from the Ministry of Internal Affairs and Communications. The population of Tokyo’s 23 wards will start declining after reaching a peak of 13.35 million by 2020, according to forecasts from the Tokyo Metropolitan Government.
Tokyu, the Tokyo region’s fourth-largest train operator, last month opened Hikarie in Shibuya ward, which houses 26 restaurants, about 200 shops and sales outlets, and a 1,972-seat theater. About 14 million people will visit a year, said Isao Watanabe, an executive officer at the Tokyo-based company.
“We have great hopes for the new building,” he said. “We’re sure it will increase the number of people using our trains as well.” Tokyu also operates hotels, supermarkets and entertainment facilities.
JR East, the largest train operator in the Tokyo area, is working to turn Tokyo Station in the Marunouchi financial district into a tourist destination. Plans includes adding more shops, restoring rooftop domes destroyed in World War II and building a plaza in front of the station that will be lit up at night. An expanded 150-room hotel will also open in October.
The Tokyo-based rail company is trying to increase its share of revenue from shops, hotels and offices to almost 40 percent from about 30 percent by the year ending March 2019.
“The railway companies have to put their energy into expanding other forms of revenue to grow,” said Ryota Himeno, an analyst at Barclays Capital Japan Ltd. “Train travel isn’t going to increase when the population is shrinking.”
• Genentech (RHHBY) to Take Part in Breakthrough ALZ Trial More...
• Pfizer Inc. (PFE)'s Torisel Fails Phase III Renal Cell Carcinoma Study in Showdown Against Bayer HealthCare (BAY)'s Nexavar More...
• Newron Pharmaceuticals (NWRN) PD Drug Succeeds in Phase III, $26 Million Zambon Pact Sealed More...
• Elevation Pharmaceuticals Announces Positive Phase 2b Results for EP-101 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) More...
• Cytomedix Inc. (CMXI) Announces Expansion of Phase 2 Study to Treat Post-Acute Ischemic Stroke at Up to 15 U.S. Clinical Sites More...
• Baxter International, Inc. (BAX) Announces ADVATE Approval in China for the Treatment of Hemophilia A More...
• Why Both Men and Women View Women in Sexy Ads as Objects, Not Humans, Universite Libre de Bruxelles Study More...
• Girls Take Longer to Heal From Concussions, Michigan State University Study More...
• Looks Matter More Than Reputation When It Comes to Trusting People With Our Money, University of Warwick Study More...
• Two-Drug Combo Helps Teens With Migraines, GlaxoSmithKline (GSK) Reveals More...
• Feeding Tube May Flare Some Ulcer Risks, Brown University Study More...
• Star Scientific , Inc. Announces Patent Claims for Synthesis of Anatabine Granted by US PTO More...
• Oramed Pharmaceuticals Inc. (ORMP.OB) Granted Israeli Patent for Its Core Technology in Oral Delivery of Proteins More...
• USPTO Grants Codexis, Inc. (CDXS) Patent for Enzymes Used in Hep-C Therapeutics More...
• National Institute for Clinical Excellence (NICE) Reverses Earlier Decision, Backs Johnson & Johnson (JNJ)'s Zytiga More...
• Bristol-Myers Squibb Company (BMY)' Plavix's New Generic Status Could be Boon for Patients More...
• Amneal Pharmaceuticals Upgrades Generic Metformin Family by Listening to Customers More...
• Pfizer Inc. (PFE) Axes 50 Jobs More...
• Ra Pharmaceuticals Closes $8.6 Million Second Tranche of $27 Million Series A More...
• NuMe Health Completes $1.5 Million Series A Financing to Advance Its First Cobiotic™ Aimed at Helping Prediabetics Maintain Healthy Blood Glucose Levels More...
• Piramal Healthcare Limited to Buy US Drug Data Firm for $635 Million More...
• Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Open to More M&A Deals More...
• GlaxoSmithKline (GSK) Completes Transaction to Increase Its Ownership in Theravance, Inc. (THRX) More...
• Intuitive Bio Acquires Assets of GenTel BioSciences, Inc. More...
• Newron Pharmaceuticals (NWRN) PD Drug Succeeds in Phase III, $26 Million Zambon Pact Sealed More...
• Plexpress Announces Collaboration With Admescope More...
• Avalanche Biotechnologies, Inc. and Lonza Inc. Announce Global Manufacturing Collaboration for Adeno-associated Viral Vectors for Gene Therapy More...
• Fibrocell Science, Inc. Announces Exclusive License Agreement with University of California, Los Angeles (UCLA) on Dermal Cell Research to Advance the Development of Personalized Cell Therapies More...
• The Biodesign Institute at Arizona State University Taps HighRes Biosolutions for Simplifying Upstream Sample Preparation of Protein Microarrays More...
• Boudazin Named President and CEO of Boiron More...
• Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer More...
• Verdezyne, Inc. Names Ray W. Miller as Chief Business Officer More...
• DNAnexus, Inc. Appoints Marc Olesen as President and COO More...
• Applied DNA Sciences, Inc. (APDN) Reports Fiscal Second Quarter 2012 Results More...
• Aoxing Pharmaceutical Company Inc. (AXN) Announces Third Quarter Fiscal 2012 Financial and Operational Results More...
• Angiotech Pharmaceuticals, Inc. (ANPI) Announces Financial Results for the First Quarter Ended March 31, 2012 More...
• Cytomedix Inc. (CMXI) Reports First Quarter 2012 Financial Results More...
• Catalyst Pharmaceutical Research Announces First Quarter 2012 Financial Results More...
• Viropro Inc. (VPRO) to Unlock Value from its Biosimilars Portfolio; Creates a Biosimilars Technology Subsidiary in Canada More...
• Pfizer Inc. (PFE)'s Torisel Fails Phase III Renal Cell Carcinoma Study in Showdown Against Bayer HealthCare (BAY)'s Nexavar More...
• Newron Pharmaceuticals (NWRN) PD Drug Succeeds in Phase III, $26 Million Zambon Pact Sealed More...
• Elevation Pharmaceuticals Announces Positive Phase 2b Results for EP-101 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) More...
• Cytomedix Inc. (CMXI) Announces Expansion of Phase 2 Study to Treat Post-Acute Ischemic Stroke at Up to 15 U.S. Clinical Sites More...
• Baxter International, Inc. (BAX) Announces ADVATE Approval in China for the Treatment of Hemophilia A More...
• Why Both Men and Women View Women in Sexy Ads as Objects, Not Humans, Universite Libre de Bruxelles Study More...
• Girls Take Longer to Heal From Concussions, Michigan State University Study More...
• Looks Matter More Than Reputation When It Comes to Trusting People With Our Money, University of Warwick Study More...
• Two-Drug Combo Helps Teens With Migraines, GlaxoSmithKline (GSK) Reveals More...
• Feeding Tube May Flare Some Ulcer Risks, Brown University Study More...
• Star Scientific , Inc. Announces Patent Claims for Synthesis of Anatabine Granted by US PTO More...
• Oramed Pharmaceuticals Inc. (ORMP.OB) Granted Israeli Patent for Its Core Technology in Oral Delivery of Proteins More...
• USPTO Grants Codexis, Inc. (CDXS) Patent for Enzymes Used in Hep-C Therapeutics More...
• National Institute for Clinical Excellence (NICE) Reverses Earlier Decision, Backs Johnson & Johnson (JNJ)'s Zytiga More...
• Bristol-Myers Squibb Company (BMY)' Plavix's New Generic Status Could be Boon for Patients More...
• Amneal Pharmaceuticals Upgrades Generic Metformin Family by Listening to Customers More...
• Pfizer Inc. (PFE) Axes 50 Jobs More...
• Ra Pharmaceuticals Closes $8.6 Million Second Tranche of $27 Million Series A More...
• NuMe Health Completes $1.5 Million Series A Financing to Advance Its First Cobiotic™ Aimed at Helping Prediabetics Maintain Healthy Blood Glucose Levels More...
• Piramal Healthcare Limited to Buy US Drug Data Firm for $635 Million More...
• Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Open to More M&A Deals More...
• GlaxoSmithKline (GSK) Completes Transaction to Increase Its Ownership in Theravance, Inc. (THRX) More...
• Intuitive Bio Acquires Assets of GenTel BioSciences, Inc. More...
• Newron Pharmaceuticals (NWRN) PD Drug Succeeds in Phase III, $26 Million Zambon Pact Sealed More...
• Plexpress Announces Collaboration With Admescope More...
• Avalanche Biotechnologies, Inc. and Lonza Inc. Announce Global Manufacturing Collaboration for Adeno-associated Viral Vectors for Gene Therapy More...
• Fibrocell Science, Inc. Announces Exclusive License Agreement with University of California, Los Angeles (UCLA) on Dermal Cell Research to Advance the Development of Personalized Cell Therapies More...
• The Biodesign Institute at Arizona State University Taps HighRes Biosolutions for Simplifying Upstream Sample Preparation of Protein Microarrays More...
• Boudazin Named President and CEO of Boiron More...
• Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer More...
• Verdezyne, Inc. Names Ray W. Miller as Chief Business Officer More...
• DNAnexus, Inc. Appoints Marc Olesen as President and COO More...
• Applied DNA Sciences, Inc. (APDN) Reports Fiscal Second Quarter 2012 Results More...
• Aoxing Pharmaceutical Company Inc. (AXN) Announces Third Quarter Fiscal 2012 Financial and Operational Results More...
• Angiotech Pharmaceuticals, Inc. (ANPI) Announces Financial Results for the First Quarter Ended March 31, 2012 More...
• Cytomedix Inc. (CMXI) Reports First Quarter 2012 Financial Results More...
• Catalyst Pharmaceutical Research Announces First Quarter 2012 Financial Results More...
• Viropro Inc. (VPRO) to Unlock Value from its Biosimilars Portfolio; Creates a Biosimilars Technology Subsidiary in Canada More...
Nifty Trading Tips & Outlook
Our yesterday's buy positions around 4872 ( Spot Nifty ), We are looking at 4950-5000 levels to square off. One may not look for short Nifty as a bounce is expected due to Facebook IPO effect. Cover up short positions and one may buy Nifty for two trading sessions.
Check out our previous recommendation here
 |
| Rosetta Genomics |
Trading Tip : Stock may have seen all upside for now and may be good for long term investment, buy on dips.
Press Release:
Rosetta Genomics Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that Novitas, the designated Medicare Administrative Contractor for the Company's miRview(R) mets^2 assay, has informed Rosetta that it plans to cover this assay for all Medicare beneficiaries. MiRview(R) mets^2 accurately identifies the primary tumor of origin in primary and metastatic cancer including Cancer of Unknown or Uncertain Primary ("CUP").
"This is a major commercial achievement for Rosetta Genomics as Medicare coverage is a critical step toward widespread commercial adoption and payment for our lead diagnostic assay, miRview(R) mets^2, and enables access to this clinically valuable test to Medicare patients. This decision is important not only because Medicare is the largest U.S. payor, covering a large percentage of the patients for whom miRview(R) mets^2 has been ordered historically and would be expected to be ordered in the future, but also because private payors often look to Medicare's decisions when setting their own reimbursement policies," noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "We are particularly pleased with how rapidly we obtained Medicare coverage, as we launched our direct selling effort in the U.S. just one year ago.
"The decision by Novitas to cover the miRview(R) mets^2 assay reflects the clinical importance of determining the tumor origin in hard-to-diagnose metastatic cancers and CUP. This is particularly important as new, targeted cancer treatments are developed for site-specific cancers. We believe that the miRview(R) mets^2 assay is an important tool that can improve the ability of physicians to accurately diagnose CUP in order to optimize treatment plans," added Mr. Berlin.
The policy will cover the 45 million Medicare beneficiaries and will enable Rosetta to provide the miRview(R) mets2 assay for Medicare beneficiaries throughout the U.S. at no cost to the patient, thereby eliminating an adoption barrier for the physician ordering the test and for the patient. Novitas' decision is based on the extensive body of clinical data published in peer-reviewed journals from clinical studies conducted internally as well as at leading institutions. Once the Novitas decision is finalized with respect to reimbursement level, we will focus our efforts on obtaining appropriate coverage and reimbursement from commercial payors.
"This coverage decision will allow all appropriate Medicare patients access to the miRview(R) mets^2 assay and further recognizes the value that our assays are delivering to physicians, payors and patients. We look forward to continuing our dialogue with Novitas, and to their final decision on reimbursement level within the coming weeks," concluded Mr. Berlin.
About miRview(R) Products miRview(R) are a series of microRNA-based diagnostic products offered by Rosetta Genomics. miRview(R) mets and miRview(R) mets^2 accurately identify the primary tumor type in primary and metastatic cancer including Cancer of Unknown Primary (CUP). miRview(R) squamous accurately identifies the squamous subtype of non-small cell lung cancer, which carries an increased risk of severe or fatal internal bleeding and poor response to treatment for certain therapies. miRview(R) meso diagnoses mesothelioma, a cancer connected to asbestos exposure. miRview(R) lung accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. miRview(R) kidney accurately classifies the four most common kidney tumors: Clear Cell Renal Cell Carcinoma (RCC), Papillary RCC, Chromophobe RCC and Oncocytoma. miRview(R) tests are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview(R) mets and miRview(R) mets^2 test, 60,000 from miRview(R) squamous, 60,000 from miRview(R) meso, 54,000 from miRview(R) kidney and more than 1 million patients worldwide from miRview(R) lung. The Company's tests are offered directly by Rosetta Genomics in the U.S., and through distributors around the globe. For more information, please visit www.mirviewdx.com . Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.
About Rosetta Genomics Rosetta Genomics develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, the Company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. The Company's miRview(R) product line is commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. To learn more, please visit www.rosettagenomics.com .
Forward-Looking Statements Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the expectation that private-sector payors would look to Medicare's decisions when setting their own reimbursement policies and that we will be able to obtain appropriate coverage and reimbursement from commercial payors, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which may never lead to commercially accepted products or services; Rosetta's ability to obtain, maintain and protect its intellectual property; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's need and ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its products and services; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; the ability to obtain a formal agreement for Medicare coverage and to maintain an equitable reimbursement valuation; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2011 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
Press Release:
Rosetta Genomics Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that Novitas, the designated Medicare Administrative Contractor for the Company's miRview(R) mets^2 assay, has informed Rosetta that it plans to cover this assay for all Medicare beneficiaries. MiRview(R) mets^2 accurately identifies the primary tumor of origin in primary and metastatic cancer including Cancer of Unknown or Uncertain Primary ("CUP").
"This is a major commercial achievement for Rosetta Genomics as Medicare coverage is a critical step toward widespread commercial adoption and payment for our lead diagnostic assay, miRview(R) mets^2, and enables access to this clinically valuable test to Medicare patients. This decision is important not only because Medicare is the largest U.S. payor, covering a large percentage of the patients for whom miRview(R) mets^2 has been ordered historically and would be expected to be ordered in the future, but also because private payors often look to Medicare's decisions when setting their own reimbursement policies," noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "We are particularly pleased with how rapidly we obtained Medicare coverage, as we launched our direct selling effort in the U.S. just one year ago.
"The decision by Novitas to cover the miRview(R) mets^2 assay reflects the clinical importance of determining the tumor origin in hard-to-diagnose metastatic cancers and CUP. This is particularly important as new, targeted cancer treatments are developed for site-specific cancers. We believe that the miRview(R) mets^2 assay is an important tool that can improve the ability of physicians to accurately diagnose CUP in order to optimize treatment plans," added Mr. Berlin.
The policy will cover the 45 million Medicare beneficiaries and will enable Rosetta to provide the miRview(R) mets2 assay for Medicare beneficiaries throughout the U.S. at no cost to the patient, thereby eliminating an adoption barrier for the physician ordering the test and for the patient. Novitas' decision is based on the extensive body of clinical data published in peer-reviewed journals from clinical studies conducted internally as well as at leading institutions. Once the Novitas decision is finalized with respect to reimbursement level, we will focus our efforts on obtaining appropriate coverage and reimbursement from commercial payors.
"This coverage decision will allow all appropriate Medicare patients access to the miRview(R) mets^2 assay and further recognizes the value that our assays are delivering to physicians, payors and patients. We look forward to continuing our dialogue with Novitas, and to their final decision on reimbursement level within the coming weeks," concluded Mr. Berlin.
About miRview(R) Products miRview(R) are a series of microRNA-based diagnostic products offered by Rosetta Genomics. miRview(R) mets and miRview(R) mets^2 accurately identify the primary tumor type in primary and metastatic cancer including Cancer of Unknown Primary (CUP). miRview(R) squamous accurately identifies the squamous subtype of non-small cell lung cancer, which carries an increased risk of severe or fatal internal bleeding and poor response to treatment for certain therapies. miRview(R) meso diagnoses mesothelioma, a cancer connected to asbestos exposure. miRview(R) lung accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. miRview(R) kidney accurately classifies the four most common kidney tumors: Clear Cell Renal Cell Carcinoma (RCC), Papillary RCC, Chromophobe RCC and Oncocytoma. miRview(R) tests are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview(R) mets and miRview(R) mets^2 test, 60,000 from miRview(R) squamous, 60,000 from miRview(R) meso, 54,000 from miRview(R) kidney and more than 1 million patients worldwide from miRview(R) lung. The Company's tests are offered directly by Rosetta Genomics in the U.S., and through distributors around the globe. For more information, please visit www.mirviewdx.com . Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.
About Rosetta Genomics Rosetta Genomics develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, the Company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. The Company's miRview(R) product line is commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. To learn more, please visit www.rosettagenomics.com .
Forward-Looking Statements Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the expectation that private-sector payors would look to Medicare's decisions when setting their own reimbursement policies and that we will be able to obtain appropriate coverage and reimbursement from commercial payors, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which may never lead to commercially accepted products or services; Rosetta's ability to obtain, maintain and protect its intellectual property; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's need and ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its products and services; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; the ability to obtain a formal agreement for Medicare coverage and to maintain an equitable reimbursement valuation; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2011 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
 |
| iPhone |
According to The Wall Street Journal, Apple's Asian suppliers will start producing screens measuring 4 inches diagonally, up from the 3.5 inches featured on the smartphone dating back to its 2007 debut.
Apple would not comment on the report, which cites "people familiar with the situation."
The iPhone has one of the smallest screens in the smartphone market at 3.5 inches. Most of the devices rivaling Apple's smartphone use touchscreens that measure at least 4 inches, including Samsung'srecently announced Galaxy S III and the HTC One X.
A potential downside could be how this reportedly larger screen impacts the overall size of the iPhone. That smaller size also makes it much easier to carry in your pocket, for example.
( Source: USA Today )
It seems like a simple enough fix: Send an email instead of a letter and conserve both paper and the gasoline (or electricity) that powers the mail truck. But while you may not think much about your email after clicking the "send" button, it embarks upon a lightning-fast--but slightly complicated--journey through cables, an energy-saving data center (why else would Google want to show off the email process?), and back out to cables and to your recipient. Check it out in the video above.
Verizon Will Suspend Remaining 3G Unlimited Data Plans This Summer
Via FierceWireless: Should Verizon’s current 3G customers decide to migrate toward 4G LTE pastures, their $30 unlimited data plans won’t be going with them. Verizon CFO Fran Shammo announced at a J.P. Morgan conference today that the company’s “grandfathered” 3G customers will have to purchase shared data plans if they upgrade to devices that are compatible with the newer LTE network. Till now, customers have been able to stay on unlimited plans as long as they had signed on before Verizon introduced tiered-pricing last July. The new shared plans will allow customers to connect multiple devices under one data plan, will arrive this summer, but Shammo did not share pricing information.
The announcement comes two weeks after AT&T CEO Randall Stephenson said his company’s unlimited data plan, which it pulled in 2010, was his “only regret.”
Facebook Adds 83.8 Million Shares To IPO
Via CNN: Facebook has increased the size of its IPO and is now looking to raise $16 billion in total (at the higher end of its bracket of $34 to $38 per share). In its recent amendment, Facebook added 83.8 million shares to its S-1 filing, from share sales by early investors, in addition to the extra 50.6 million it added yesterday, taking its total past 421 million shares.
With Knowledge Graph, Google Can Finally Tell The Difference Between Apple Inc. And Apples
Google today launched the Knowledge Graph, a new search engine feature that helps users quickly find relevant information using semantic search technology. Now, when a user conducts a search, Google will return results with two right-hand-side panels that will include additional relevant information on the search subject, such as biographical data, as well as a list of related topics. The Knowledge Graph attempts to make the search process more user-friendly by providing information about a search result’s relationship to other, previously scattered pieces of data.
The Knowledge Graph is powered by both private and public databases, including Wikipedia, Freebase, and the CIA’s World Factbook, that feed into the graph’s current storehouse of information on more than 500 million people, places, and things. It’s the company’s most significant search engine enhancement since 2007, when its Universal Search feature sprinkled video, image, and shopping results into its main list of search results.
The Knowledge Graph will roll out nationwide over the next few days. The announcement comes one day after Microsoft made its newly launched slew of social features for competitor Bing available to all U.S. users.
Flipboard Gets Audio From SoundCloud, NPR, PRI
Social reader Flipboard is adding audio content to its list of sourse streams. Social music site SoundCloud, as well as audio content makers PRI and NPR, are its first partners. Flipboard is reaching out to users who are visually impaired--the app now integrates with Apple's VoiceOver feature to read text out loud. Flipboard's SoundCloud partnership is breaking the app reader mould set by the pre-audio Flipboard, and other reader apps like Zite and Google Currents. But considering Flipboard's emphasis on social content--"Everything we do at Flipboard is fundamentally social," Flipboard founder Evan Doll once told me--SoundCloud, a source of music from friends, is entirely consistently with the Flipboard flavor.
Facebook Hires Lightbox App Builder Team
Facebook has hired the team behind the photo app Lightbox, in a last minute pre-IPO shop--further evidence that Facebook cares a good deal about how users view and share photos on the social network. Lightbox founders Thai Tran and Nilesh Patel made the announcement on their blog yesterday, saying Facebook wouldn't be acquiring the company itself, though Lightbox would no longer be accepting new users. Patel and Tran will be joining a team and leader that's grown up since Facebook's early college-style all-night coding sessions to a more careful, considered and deliberate product building culture.
Social Ad Spending To Reach $10B Soon, But How Much For Facebook?
A new survey from BIA/Kelsey has looked at the trends in advertising on social media and concluded that by 2016 it'll be a market topping $10 billion per annum, mainly as display ads. For context, some $3.8 billion was spent on these ads in 2011, so phenomenal growth is predicted. In the very week Facebook IPOs this sounds like great news, except for different data coming from Wordstream that suggests Facebook's adverts have less reach and are less effective in generating click-throughs than traditional web ads served up by Google. Meanwhile car giant GM is reported by the Wall Street Journal to be killing its $10 million Facebook advertising campaign because it simply didn't work to generate sales. GM will continue to use free channels on Facebook to generate brand awareness, but it's decision means Facebook will lose out on income.
Via FierceWireless: Should Verizon’s current 3G customers decide to migrate toward 4G LTE pastures, their $30 unlimited data plans won’t be going with them. Verizon CFO Fran Shammo announced at a J.P. Morgan conference today that the company’s “grandfathered” 3G customers will have to purchase shared data plans if they upgrade to devices that are compatible with the newer LTE network. Till now, customers have been able to stay on unlimited plans as long as they had signed on before Verizon introduced tiered-pricing last July. The new shared plans will allow customers to connect multiple devices under one data plan, will arrive this summer, but Shammo did not share pricing information.
The announcement comes two weeks after AT&T CEO Randall Stephenson said his company’s unlimited data plan, which it pulled in 2010, was his “only regret.”
Facebook Adds 83.8 Million Shares To IPO
Via CNN: Facebook has increased the size of its IPO and is now looking to raise $16 billion in total (at the higher end of its bracket of $34 to $38 per share). In its recent amendment, Facebook added 83.8 million shares to its S-1 filing, from share sales by early investors, in addition to the extra 50.6 million it added yesterday, taking its total past 421 million shares.
With Knowledge Graph, Google Can Finally Tell The Difference Between Apple Inc. And Apples
Google today launched the Knowledge Graph, a new search engine feature that helps users quickly find relevant information using semantic search technology. Now, when a user conducts a search, Google will return results with two right-hand-side panels that will include additional relevant information on the search subject, such as biographical data, as well as a list of related topics. The Knowledge Graph attempts to make the search process more user-friendly by providing information about a search result’s relationship to other, previously scattered pieces of data.
The Knowledge Graph is powered by both private and public databases, including Wikipedia, Freebase, and the CIA’s World Factbook, that feed into the graph’s current storehouse of information on more than 500 million people, places, and things. It’s the company’s most significant search engine enhancement since 2007, when its Universal Search feature sprinkled video, image, and shopping results into its main list of search results.
The Knowledge Graph will roll out nationwide over the next few days. The announcement comes one day after Microsoft made its newly launched slew of social features for competitor Bing available to all U.S. users.
Flipboard Gets Audio From SoundCloud, NPR, PRI
Social reader Flipboard is adding audio content to its list of sourse streams. Social music site SoundCloud, as well as audio content makers PRI and NPR, are its first partners. Flipboard is reaching out to users who are visually impaired--the app now integrates with Apple's VoiceOver feature to read text out loud. Flipboard's SoundCloud partnership is breaking the app reader mould set by the pre-audio Flipboard, and other reader apps like Zite and Google Currents. But considering Flipboard's emphasis on social content--"Everything we do at Flipboard is fundamentally social," Flipboard founder Evan Doll once told me--SoundCloud, a source of music from friends, is entirely consistently with the Flipboard flavor.
Facebook Hires Lightbox App Builder Team
Facebook has hired the team behind the photo app Lightbox, in a last minute pre-IPO shop--further evidence that Facebook cares a good deal about how users view and share photos on the social network. Lightbox founders Thai Tran and Nilesh Patel made the announcement on their blog yesterday, saying Facebook wouldn't be acquiring the company itself, though Lightbox would no longer be accepting new users. Patel and Tran will be joining a team and leader that's grown up since Facebook's early college-style all-night coding sessions to a more careful, considered and deliberate product building culture.
Social Ad Spending To Reach $10B Soon, But How Much For Facebook?
A new survey from BIA/Kelsey has looked at the trends in advertising on social media and concluded that by 2016 it'll be a market topping $10 billion per annum, mainly as display ads. For context, some $3.8 billion was spent on these ads in 2011, so phenomenal growth is predicted. In the very week Facebook IPOs this sounds like great news, except for different data coming from Wordstream that suggests Facebook's adverts have less reach and are less effective in generating click-throughs than traditional web ads served up by Google. Meanwhile car giant GM is reported by the Wall Street Journal to be killing its $10 million Facebook advertising campaign because it simply didn't work to generate sales. GM will continue to use free channels on Facebook to generate brand awareness, but it's decision means Facebook will lose out on income.
"Indonesia looks like it has hit the sweet spot, whereas India is nursing a headache from its latest boom," says Frederic Neumann, Co-Head of Asian Economic Research at HSBC.
While the two economies aren't similar in terms of size, with India's population of 1.2 billion and Indonesia's at 240 million, the countries share many similarities, leading to comparisons. Both have a burgeoning consumer base and are democracies with an investment grade rating.
India's economy has hit a rough spot with the slowest pace of growth in three years with the government unable to deliver on economic reforms. On the other hand, Indonesia has won favor with investors over the past few years.
That's leading Neumann and others to call for Indonesia to be included in the lineup of top global emerging markets. "The term BRICs really misses out on some of the key developments of our time. Indonesia has solid public finances, strong growth, a burgeoning consumer market, and plenty of resources to keep the economy afloat for many years," says Neumann.
On the other hand, India, according to Goldman Sachs' Jim O'Neill, the man who coined the term in 2001, is the BRIC that has disappointed. Late last year O'Neill said that India's poor record on productivity, foreign direct investment (FDI) and policy reform had made it the most disappointing among the four biggest developing economies - Brazil, Russia, India and China.
For example, India's fiscal deficit target of 5.1 per cent is wider than those of its BRIC peers. Its forecast deficit is more than four times Brazil's estimated 2012 budget gap of 1.2 per cent of output.
"It is difficult to see how India can turn around in the short term. It could in the next couple of years, but that is an eternity from investors' point of view, " says Neumann.
He adds that investors have already voted with their feet taking money out of India. The latest evidence of this was in the month of April when offshore investors withdrew some USD 403 million out of Indian equities and bonds, according to Reuters data.
While it is difficult to estimate how much of India's loss has been Indonesia's gain, market watchers say many investors have been increasingly looking at Indonesia as an alternative to India.
"To a large extent investor interest has moved to Indonesia," Robert Prior-Wandesford, Director, Asian Economics at Credit Suisse told CNBC. "Indonesia's equity market is hugely better than that of India and in part at the cost of India."
While the Bombay Stock Exchange's Sensex was the worst performing major global index in 2011 falling almost 25 per cent, the Jakarta Composite Index gained over three percent.
Besides delivering better returns, Indonesia is also catching up with India when it comes to economic growth. India's gross domestic product (GDP) is expected to expand at just under 7 per cent in the current fiscal year, which began April 1, while Indonesia is expected to deliver 6 to 7 per cent growth over the next couple of years, say analysts.
Even on trade, Indonesia scores over India. According to brokerage CLSA's latest forecast Indonesia's current account deficit in 2012 will be just 0.8 per cent of GDP, while India's will come in at around 3.9 per cent.
Rajeev Malik, Senior Economist at CLSA, says in Indonesia's case, net Foreign Direct Investment (FDI) will offset the current account deficit. In India's case, he points out, an estimated net FDI inflow of USD 15-20 billion will be well short of the current account deficit.
"They are doing better although they are not as big an economy as India," he says.
Credit Suisse's Wandesford says Indonesia reminds him of India three to four years ago, when there was a huge euphoria over the growth opportunity it offered foreign investors and companies. "In 2005-2008 India could do no wrong, now it is Indonesia."
India, which was awarded an investment grade rating by Standard and Poor's in 2007 is now under threat of losing it, with the ratings agency last month downgrading its credit outlook to negative. By contrast, both Fitch and Moody's upgraded Indonesia to investment grade in December and January, respectively.
Size matters
But despite the growing pessimism around India, most experts feel that it is not time yet to write off a country of a billion-plus people, if on nothing else than its sheer size.
Some argue that while there is a case for Indonesia to join the BRICs, it shouldn't be at the cost of India as they both have different comparative advantages. While one is a commodity economy, the other is a services oriented one and an investor, for example, can't completely replicate his menu of Indian stocks in Indonesia, say analysts.
"BRIC investors have a 20-year horizon and India will finally deliver in the long term," says Neumann.
China Mobile is the only Chinese operator that does not officially carry the iPhone because its homegrown 3G technology is not supported by the chips used in current iPhone models.
Analysts have said next-generation iPhones will likely use a Qualcomm chip that would support China Mobile's network, removing the key technology barrier for a deal.
"We've been actively talking to Apple on how we can cooperate," China Mobile Chairman Xi Guohua, who assumed the post in March, told a shareholders meeting. "I can't give you too many details, but I'd like to repeat that both sides do hope to boost our cooperation," Xi added after the meeting.
He made the comments in response to a question about when China Mobile would sign a deal for the iPhone. Rivals China Unicom and China Telecom have already signed contracts with Apple.
Xi also said China Mobile is trying to expand its services outside mainland China by offering 4G services in Hong Kong this year and is hoping to provide mobile service between the United States and China.
However, media reports have said U.S. authorities might deny its application due to security concerns.
"We want to become a more global company. For that to happen, we are interested in tapping other markets such as Hong Kong and the United States," Xi said.
"We have applied to the United States for a license, but it's not been rejected yet. Rather, it's undergoing the relevant procedure. We hope the U.S. government will give us their approval soon for us to expand our services there."
TD-LTE Trials
China Mobile also said it was expanding tests of its latest generation TD-LTE mobile network. The company has completed initial testing with 850 base stations in six cities, such as Hangzhou in China's east, and expects to complete the next phase of tests by June 2013, executives said earlier this year.
TD-LTE refers to "time division long-term evolution" technology that allows for more voice connections, faster data speeds and easier network upgrades.
China Mobile executives said on Wednesday the trials will be expanded to 10 cities, including Beijing, with the number of base stations increasing to more than 20,000 this year.
There are now 72 LTE operators that have launched commercial services, including 25 networks launched so far in 2012, according to a May report by the Global mobile Suppliers Association (GSA).
Commercial LTE services are already available in Asia in Australia, Hong Kong, India, Japan, the Philippines, Singapore and South Korea, the GSA said.
China Mobile shares are up about 13 percent this year, outperforming the Hang Seng Index's rise of about 5 percent.
The carrier said subscribers in March rose to 667.20 million, more than twice the population of the United States, including 59.56 million 3G subscribers. (Source: Reuters)
